<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03350165</url>
  </required_header>
  <id_info>
    <org_study_id>K-877-FL-01</org_study_id>
    <nct_id>NCT03350165</nct_id>
  </id_info>
  <brief_title>A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Company, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate
      the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 27, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Actual">April 3, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: % Change from baseline to Week 24 in hepatic fat fraction by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events and adverse drug reactions that occurred after the administration of the study drug</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in noninvasive imaging biomarkers (MRI-PDFF in %, MRE in kPa, Transient elastography in kPa)</measure>
    <time_frame>From baseline upto week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical laboratory tests (AST in IU/L, ALT in IU/L, γ-GTP in IU/L)</measure>
    <time_frame>From baseline upto week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in noninvasive biomarkers (Cytokeratin 18 in U/L, Hyaluronic acid in ng/mL, Type IV collagen 7S in ng/mL, M2BPGi in no unit)</measure>
    <time_frame>From baseline upto week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in noninvasive biomarkers (NAFLD fibrosis score)</measure>
    <time_frame>From baseline upto week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in noninvasive biomarkers (FIB4 index)</measure>
    <time_frame>From baseline upto week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in noninvasive biomarkers (NAFIC score)</measure>
    <time_frame>From baseline upto week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in noninvasive biomarkers (ELF test)</measure>
    <time_frame>From baseline upto week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ≥ 30% reduction in hepatic fat fraction (MRI-PDFF)</measure>
    <time_frame>From baseline upto week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ≥ 15% reduction in liver stiffness (MRE)</measure>
    <time_frame>From baseline upto week 72</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-877 (pemafibrate) tablet twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877</intervention_name>
    <description>0.2mg tablet</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>pemafibrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>K-877 matching placebo tablet</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients show presence of hepatic fat fraction as defined by ≥ 10% on MRI-PDFF at
             Screening

          2. Patients show presence of liver stiffness as defined by ≥ 2.5 kPa on MRE at Screening

          3. Patients have an ALT above the upper limits of normal (30 IU/L for females and 40 IU/L
             for males) at Screening

          4. Patients with NAFLD had to be age 20 years or older at written informed consent(ICF)

        Exclusion Criteria:

          1. Current of significant alcohol consumption (significant alcohol consumption is defined
             as more than 210 g/week in males and more than 140 g/week in females, on average)

          2. Planned use of Contraindicated Medications from written ICF to end of treatment.

          3. BMI &lt; 22 kg/m2 at Screening

          4. Uncontrolled diabetes mellitus as defined by a HbA1c(NGSP) ≥ 8.0％ at Screening

          5. eGFR &lt; 30 mL/min/1.73m2 or Dialysis patient

          6. Cirrhosis

          7. Biliary obstruction

          8. Patients were excluded if they had evidence of other forms of liver disease shown by
             the following:

               -  Hepatitis B or Hepatitis C

               -  Autoimmune hepatitis（AIH）

               -  Primary biliary cirrhosis（PBC）

               -  Primary Sclerosing Cholangitis（PSC）

               -  Drug-induced liver injury

               -  hyperthyroidism, Wilson's disease, hemochromatosis, alpha-1-antitrypsin disease

          9. Those with complicating malignant neoplasm or those judged to be at a high risk of
             recurrence

         10. Patients with contraindications to MRI imaging

         11. Patients who gave 200 mL or more of blood within 1 month before the administration of
             the study drug, or 400 mL or more of blood within 4 months before the administration
             of the study drug

         12. Patients with a history of serious drug allergies (such as anaphylactic shock)

         13. Pregnancy, breast feeding, planned pregnancy

         14. Patients who were participating in another clinical study at the time of consent was
             obtained or who received study drugs other than the placebo less than 16 weeks before
             consent was obtained

         15. Patients who have previously been administered pemafibrate

         16. Patients who have been determined inappropriate by the investigator or subinvestigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryohei Tanigawa</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Development Dept. Ⅰ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aomori Prefectural Central Hospital</name>
      <address>
        <city>Aomori, Aomori</city>
        <zip>030-8553</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahikawa Medical University</name>
      <address>
        <city>Asahikawa, Hokkaido</city>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuwa Clinic</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SeireiHamamatsu General Hospital</name>
      <address>
        <city>Hamamatsu, Shizuoka</city>
        <zip>430-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital</name>
      <address>
        <city>Hamamatsu, Shizuoka</city>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwata City Hospital</name>
      <address>
        <city>Iwata, Shizuoka</city>
        <zip>438-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chutoen General Medical Center</name>
      <address>
        <city>Kakegawa, Shizuoka</city>
        <zip>436-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume, Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital</name>
      <address>
        <city>Niigata, Niigata</city>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogaki Municipal Hospital</name>
      <address>
        <city>Ogaki, Gifu</city>
        <zip>503-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Otsu, Shiga</city>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital</name>
      <address>
        <city>Yamagata, Yamagata</city>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohamashi Tobu Hospital</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <zip>230-8765</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

